Information Provided By: 
Fly News Breaks for August 11, 2015
CLDX
Aug 11, 2015 | 08:20 EDT
After Celldex announced that it would likely delay filing for approval of its Rintega drug until another clinical study is completed at the end of 2015 or early 2016, Oppenheimer says that the stock's valuation only reflects the value of a single clinical asset. The firm cut its price target on the name to $42 from $45 but keeps an Outperform rating on the shares.
News For CLDX From the Last 2 Days
There are no results for your query CLDX
